Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops peptide-based therapeutics to address significant unmet medical needs. The company's pipeline includes PTG-300, an injectable hepcidin mimetic for the treatment of iron overload-related rare diseases, including beta-thalassemia and polycythemia vera; and PN-943, an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide for the treatment of inflammatory bowel disease. Protagonist Therapeutics, Inc. was founded in 2006 and is headquartered in Newark, California.